BVF Inc. IL boosted its stake in shares of ArQule, Inc. (NASDAQ:ARQL) by 122.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,436,912 shares of the biotechnology company’s stock after buying an additional 9,036,784 shares during the quarter. ArQule accounts for approximately 3.3% of BVF Inc. IL’s portfolio, making the stock its 10th largest holding. BVF Inc. IL owned 18.87% of ArQule worth $27,121,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new stake in shares of ArQule in the third quarter valued at approximately $2,220,000. First Eagle Investment Management LLC grew its position in shares of ArQule by 5.0% in the third quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock valued at $13,807,000 after purchasing an additional 591,421 shares during the last quarter. Virtu Financial LLC grew its position in shares of ArQule by 343.8% in the fourth quarter. Virtu Financial LLC now owns 129,038 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 99,964 shares during the last quarter. Northern Trust Corp grew its position in shares of ArQule by 0.9% in the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 1,385 shares during the last quarter. Finally, Deutsche Bank AG acquired a new stake in shares of ArQule in the fourth quarter valued at approximately $390,000. Institutional investors own 67.08% of the company’s stock.
Several analysts have recently commented on ARQL shares. B. Riley started coverage on shares of ArQule in a research report on Friday, February 2nd. They issued a “buy” rating and a $3.00 price target on the stock. Zacks Investment Research upgraded shares of ArQule from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Tuesday, March 20th. ValuEngine upgraded shares of ArQule from a “sell” rating to a “hold” rating in a research report on Thursday, March 15th. BidaskClub upgraded shares of ArQule from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 24th. Finally, Needham & Company LLC upgraded shares of ArQule from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. ArQule currently has an average rating of “Buy” and a consensus price target of $4.08.
NASDAQ ARQL traded up $0.30 during mid-day trading on Monday, reaching $3.18. 1,080,932 shares of the stock were exchanged, compared to its average volume of 479,762. ArQule, Inc. has a 1-year low of $0.92 and a 1-year high of $3.35. The firm has a market cap of $250.88, a P/E ratio of -8.15 and a beta of 0.81. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.98 and a current ratio of 4.98.
ArQule (NASDAQ:ARQL) last announced its earnings results on Monday, March 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.09). During the same quarter last year, the business posted ($0.10) EPS. equities analysts predict that ArQule, Inc. will post -0.31 EPS for the current year.
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.